Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Acta cir. bras ; 34(1): e20190010000007, 2019. tab, graf
Article in English | LILACS | ID: biblio-983684

ABSTRACT

Abstract Purpose: To investigate the impact of Ramipril (RAM) on the expressions of insulin-like growth factor-1 (IGF-1) and renal mesangial matrix (RMM) in rats with diabetic nephropathy (DN). Methods: The Sprague Dawley rats were divided into normal control (NC) group (n = 12), DN group (n = 11), and DN+RAM group (n = 12). The ratio of renal weight to body weight (RBT), fasting blood glucose (FBG), HbA1c, 24-h urine protein (TPU), blood urea nitrogen (BUN), creatinine (Cr), renal pathological changes, the levels of IGF-1, fibronectin (FN), type IV collagen (Col-IV), and matrix metalloproteinases (MMP)-2 were compared among the groups. Results: Compared with NC group, the RBT, FBG, HbA1c, TPU, BUN, Cr, and RMM in DN group were significantly increased (P < 0.05), the IGF-1, FN, and Col-IV were significantly upregulated (P < 0.05), while MMP was significantly downregulated (P < 0.05). Compared with DN group, the indexes except for the FBG and HbA1c in DN+RAM group were significantly improved (P < 0.05), among which IGF-1 exhibited significant positive correlation with TPU(r=0.937), FN(r=0.896) and Col-IV(r=0.871), while significant negative correlation with MMP-2 (r=-0.826) (P<0.05). Conclusion: RAM may protect the kidneys by suppressing IGF-1 and mitigating the accumulation of RMM.


Subject(s)
Animals , Male , Rats , Insulin-Like Growth Factor I/antagonists & inhibitors , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Ramipril/pharmacology , Diabetic Nephropathies/drug therapy , Mesangial Cells/drug effects , Insulin-Like Growth Factor I/metabolism , Immunohistochemistry , Fibronectins/drug effects , Fibronectins/metabolism , Rats, Sprague-Dawley , Matrix Metalloproteinases/drug effects , Matrix Metalloproteinases/metabolism , Collagen Type IV/adverse effects , Collagen Type IV/metabolism , Diabetic Nephropathies/metabolism , Mesangial Cells/metabolism
2.
Exp Anim ; 59(2): 157-70, 2010.
Article in English | MEDLINE | ID: mdl-20484849

ABSTRACT

The aim of this study was to develop and characterize a rat glomerulonephritis model, which progresses to renal fibrosis and renal failure. A single immunization of female WKY rats with more than 10 microg of recombinant alpha3(IV)NC1 protein caused severe proteinuria followed by progressive increases in plasma creatinine and blood urea nitrogen (BUN) level within 42 days. Sequential histopathological evaluation revealed crescent formation in glomeruli followed by tubular dilation and interstitial fibrosis. Hydroxyproline content and expression of type I collagen and smooth muscle actin genes in the renal cortex increased as renal dysfunction progressed. Furthermore, the TGF-beta1 level in the renal cortex also increased. In the evaluation of antinephritic agents in this model, prednisolone and mycophenolate mofetil (MMF) treatment significantly decreased plasma creatinine and BUN, and suppressed renal fibrosis and histological changes involving crescent formation, compared with the vehicle-treated nephritic rats, whereas lisinopril treatment failed to improve renal function and histology. We demonstrated that immunization of female WKY rats with a sufficient dose of recombinant alpha3(IV)NC1 induces end-stage kidney disease accompanied by renal fibrosis. The relatively short period needed to induce the disease and the high incidence of functional and structural changes were considered a great advantage of this model for clarifying the mechanisms of progressive glomerulonephritis and for evaluating agents used to treat renal failure.


Subject(s)
Autoantigens/adverse effects , Collagen Type IV/adverse effects , Glomerulonephritis/physiopathology , Kidney Failure, Chronic/physiopathology , Recombinant Proteins/adverse effects , Actins/genetics , Actins/metabolism , Animals , Collagen Type I/genetics , Collagen Type I/metabolism , Creatinine/blood , Disease Models, Animal , Female , Gene Expression , Glomerulonephritis/chemically induced , Glomerulonephritis/drug therapy , Glomerulonephritis/metabolism , Hydroxyproline/genetics , Hydroxyproline/metabolism , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/chemically induced , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/metabolism , Kidney Function Tests , Lisinopril/therapeutic use , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Prednisolone/therapeutic use , Rats , Rats, Inbred WKY , Transforming Growth Factor beta1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...